PRIMA Implant Restores Vision for 36 Months in Blind Patients

Science Corp. has announced 36-month results from its PRIMA brain-computer interface clinical trial, reporting durable vision restoration in blind patients with geographic atrophy, the advanced form of dry age-related macular degeneration.

The company released the long-term follow-up data under the headline finding that the restoration of functional vision persisted at three years — the longest durability readout Science Corp. has disclosed for the PRIMA device in this patient population.

Who is in the trial?

The study enrolled patients who are legally blind from geographic atrophy. In this condition, photoreceptors in the macula degenerate, but the inner retinal neurons and their pathway to the visual cortex remain largely intact. PRIMA is designed to bypass the damaged photoreceptors and drive the remaining retinal circuitry directly, sending visual information to the brain through the intact optic pathway.

The three-year timeframe matters clinically. Retinal implants and cortical visual prostheses have historically struggled with durability — electrode stability, encapsulation, and signal degradation over time. A 36-month demonstration of continued function addresses one of the central questions reading-room neurologists and retina specialists ask about any visual prosthesis: does it keep working?

What did the 36-month data show?

According to the company's announcement, the trial results show durable vision restoration across the follow-up period. Science Corp. describes the outcome as evidence that PRIMA-mediated visual function persists long-term in patients who were blind from geographic atrophy before implantation.

The announcement does not specify the exact number of patients carried to the 36-month timepoint, the visual acuity values achieved, or the statistical analysis plan. Those details will determine how practice-changing the result is; clinicians will want the per-protocol cohort size, the functional endpoints used, and how performance evolved between earlier timepoints and month 36.

Investigational, not cleared

PRIMA remains an investigational device. The results come from a clinical trial, not from an FDA-cleared product, and no regulatory clearance is claimed in the announcement. For monitoring units and retina clinics, this means the technology sits in the research pipeline: promising, measured in trial settings, and not yet available as standard of care.

Patients with geographic atrophy currently have no approved option that restores lost central vision, which is why a three-year durability signal — even pending full publication — draws attention.

What comes next?

The logical next steps are peer-reviewed publication of the full 36-month dataset, larger pivotal studies, and the regulatory pathway toward approval. Science Corp. says the long-term results support continued development of PRIMA for blind patients with geographic atrophy.